<DOC>
	<DOCNO>NCT01975298</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability two dos laquinimod compare Avonex®</brief_summary>
	<brief_title>A Study Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared Interferon ß-1a Administered Injection Participants With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Inclusion Criteria Subjects must confirm documented RRMS diagnosis define Revised McDonald criterion , relapse onset disease relapsingremitting disease course . Subjects must ambulatory Kurtzke EDSS score 05.5 Screening Baseline ( randomization ) visit . Subjects must stable neurological condition , relapsefree free corticosteroid treatment ( intravenous [ IV ] , IM and/or per o [ PO ] ) adrenocorticotrophic hormone ( ACTH ) , 60 day prior randomization . Subjects must experience least 1 document relapse last year prior randomization 2 relapse last 3 year prior randomization . Subjects must 18 55 year age screening , inclusive . Women childbearing potential must practice acceptable method birth control 30 day last dose treatment administer ( acceptable method birth control study include : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch , longacting injectable contraceptive doublebarrier method [ condom diaphragm spermicide ] ) . Subjects must able sign date write informed consent prior enter study . Subjects must willing able comply protocol requirement duration study . criterion may apply , please contact investigator information Subjects progressive form MS . Subjects Neuromyelitis Optica ( NMO ) . Use experimental investigational drug and/or participation drug clinical study within 6 month prior Baseline visit ( randomization ) . Use immunosuppressive agent , cytotoxic agent , include cyclophosphamide azatioprine within 12 month prior Baseline . Natalizumab ( Tysabri® ) give 6 month prior randomization AND subject John Cunningham ( JC ) virus antibody test negative Screening . Previous use Rituximab , ocrelizumab , ofatumumab allow B cell count ( CD19 ) high 80 cell /μL . Previous treatment glatiramer acetate ( Copaxone®e ) , fingolimod ( Gilenya® ) , BG12 ( Tecfidera ) , Teriflunomide ( Aubagio® ) intravenous immunoglobulin ( IVIG ) within 2 month prior Baseline . Use mitoxantrone ( Novantrone ) within 5 year prior Screening . Use mitoxantrone ( Novantrone ) &gt; 5 year screen allowed subject normal ejection fraction exceed total lifetime maximal dose . Chronic ( 30 consecutive day monthly dose , eg , intent MS disease modification ) systemic ( IV , IM PO ) corticosteroid treatment within 2 month prior Baseline . Previous use cladribine . Previous use laquinimod Avonex® IM . Treatment Interferonβ ( either 1a subcutaneous [ SC ] 1b SC ) within 60 day baseline ( earlier treatment allow reason discontinuation treatment failure Interferonβ relate safety reason . This decision take investigator ) . Previous total body irradiation total lymphoid irradiation . Previous stem cell treatment , autologous bone marrow transplantation , allogenic bone marrow transplantation . Acute infection within 2 week prior Baseline visit . Major trauma surgery within 2 week prior Baseline visit . Use moderate/strong inhibitor CYP3A4 within 2 week prior Baseline . Use inducer CYP3A4 within 2 week prior Baseline Pregnancy breast feeding . Serum level ≥ 3 time ( x ) upper limit normal ( ULN ) either ALT AST Screening . Serum direct bilirubin ≥ 2xULN Screening . Subjects clinically significant unstable medical surgical condition condition wellcontrolled allow medication permit study protocol would preclude safe complete study participation , determine medical history , physical examination , ECG , laboratory test MRI chest Xray Any acute pulmonary disorder . A central nervous system disorder MS may jeopardize participation study , include disorder demonstrate baseline MRI . A gastrointestinal disorder may affect absorption study medication . Renal disease . Thyroid disease : hyperthyroidism , hypothyroidism . Any form acute chronic liver disease . Known human immunodeficiency virus positive status . A clinical history drug and/or alcohol abuse . Unstable psychiatric disorder . A history seizure disorder , last convulsive episode within 12 month prior Screening visit . Any malignancy , exclude basal cell carcinoma , 5 year prior randomization . Twenty gadolinium enhance lesion baseline MRI . A known history sensitivity gadolinium ( Gd ) . GFR ≤ 60 mL/min screen visit . Inability successfully/safely undergo MRI scanning . Subjects underwent endovascular treatment Chronic Cerebrospinal Venous Insufficiency ( CCSVI ) . Known hypersensitivity would preclude administration laquinimod capsule , hypersensitivity : mannitol , meglumine , sodium stearyl fumarate . A known history hypersensitivity natural recombinant interferon β , human albumin , component formulation Avonex® Employees clinical study site individual involve conduct study , immediate family member individual criterion may apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>RRMS</keyword>
</DOC>